US 12,441,732 B2
Potassium salt crystal form B of phosphodiesterase type 5 inhibitor, and preparation method and use therefor
Allan Zijian Zhao, Guangzhou (CN); Yunping Mu, Guangzhou (CN); Fanghong Li, Guangzhou (CN); Zhenggang Zhao, Guangzhou (CN); and Huidan Zhu, Guangzhou (CN)
Assigned to SHENZHEN HANHUI PHARMACEUTICAL TECHNOLOGY CO., LTD., Shenzhen (CN)
Appl. No. 17/617,655
Filed by Guangzhou Huazhen Pharmaceutical Co., Ltd, Guzngzhou (CN)
PCT Filed Aug. 7, 2020, PCT No. PCT/CN2020/107811
§ 371(c)(1), (2) Date Dec. 9, 2021,
PCT Pub. No. WO2020/249139, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 201910505948.5 (CN), filed on Jun. 12, 2019.
Prior Publication US 2022/0251093 A1, Aug. 11, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 9/00 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); A61P 15/10 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 9/00 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); A61P 15/10 (2018.01); C07B 2200/13 (2013.01)] 19 Claims
 
1. A potassium salt crystal form B of a compound, wherein the compound has a structural formula shown in a formula (I), and

OG Complex Work Unit Chemistry
an X-ray powder diffraction (XRPD) pattern of the potassium salt crystal form B has characteristic peaks at the following 2θ angles: 5.71°±0.2°, 8.23°±0.2°, 11.37°±0.2°, 13.22°±0.2°, 17.09°±0.2°, 21.56°±0.2°, 23.99°±0.2°, and 25.85°±0.2°.